Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma

Table 1 Clinical and molecular characteristics according to pre-treatment NLR in 152 glioblastoma cases

Clinical or Molecular Feature	All Cases			Pre-treatment NLR						P
	All Cases			<4			≥4
	No.		%	No.		%	No.		%
Total No. of patients	152		100	103		67.8	49		32.2
Sex										0.823
Male	95		62.5	65		68.4	30		31.6
Female	57		37.5	38		66.7	19		33.3
Age, years										0.136
Mean ± SD		50.4 ± 15.4			49.2 ± 16.2			53.1 ± 13.1
≤ 60	112		73.7	80		71.4	32		28.6	0.118
> 60	40		26.3	23		57.5	17		42.5
Tumor size, cm³										0.920
Mean ± SD		60.6 ± 26.6			60.4 ± 26.1			61.0 ± 28.0
KPS										0.212
Mean ± SD		71.4 ± 14.2			70.4 ± 15.2			73.5 ± 11.6
≤ 70	78		51.3	54		69.2	24		30.8	0.731
80–100	74		48.7	49		66.2	25		33.8
Resection										0.659
Biopsy	38		25.0	28		73.7	10		26.3
Subtotal	39		25.7	26		66.7	13		33.3
Gross total	75		49.3	49		65.3	26		34.7
BMI, kg/m²										0.150
Mean ± SD		24.2 ± 3.2			23.9 ± 3.3			24.8 ± 3.1
MGMT promoter										0.975
Methylated	53		34.9	36		67.9	17		32.1
Unmethylated	99		65.1	67		67.7	32		32.3
Pre-treatment PLR										<0.001
Mean ± SD		135.0 ± 57.1			111.4 ± 34.7			184.8 ± 62.9
OS, months										<0.001
Mean ± SD		15.6 ± 11.2			17.9 ± 11.0			10.6 ± 9.8

The differences between patients with pre-treatment NLR <4 and ≥4 were compared. P value was calculated using chi-square test for categorical variables and using Student’s t-test for continuous variables
BMI Body Mass Index, KPS Karnofsky Performance Scores, MGMT O(6)-methylguanine-DNA-methyltransferase, NLR Neutrophil to Lymphocyte Ratio, OS Overall Survival, PLR Platelet to Lymphocyte Ratio

ISSN: 1471-2407